β-Amyloid Upregulates Intracellular Clusterin but not Secretory Clusterin in Primary Cultured Neurons and APP Mice

Author(s): Ping Wang, Keliang Chen, Yuehua Gu, Qihao Guo, Zhen Hong, Qianhua Zhao*

Journal Name: Current Alzheimer Research

Volume 14 , Issue 11 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Background: Previous studies have suggested that the expression of Aβ and clusterin is positively correlated. However, the causal relationship between Aβ and clusterin has not been exactly clarified.

Methods: In this study, primary hippocampal neurons were treated with Aβ42; clusterin mRNA and protein expression was assessed. Furthermore, we evaluated Aβ and clusterin protein expression in the brains of APP/PSEN1 mice, as well as serum clusterin concentration.

Results: We observed here that the exposure of primary hippocampal neurons to Aβ42 induced an overexpression of intracellular clusterin, but the level of clusterin in supernatants was not changed. Moreover, in APP/PSEN1 mice, there was a significant increase in intracellular clusterin in cortex and hippocampus, compared to age-matched WT mice, while serum clusterin level in APP/PSEN1 mice and in WT mice has no significant difference.

Conclusion: Aβ42 upregulated intracellular clusterin, but secretory clusterin did not change. These findings reveal that clusterin is upregulated by Aβ and is responsive to AD pathology, although plasma clusterin concentration is not evidenced to be a stand-alone biomarker for AD.

Keywords: Clusterin, β-amyloid, Alzheimer's disease, upregulation, intracellular clusterin, secretory clusterin.

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580): 353-6. (2002).
May PC, Lampert-Etchells M, Johnson SA, Poirier J, Masters JN, Finch CE. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer’s disease and in response to experimental lesions in rat. Neuron 5(6): 831-9. (1990).
Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer’s disease. Brain Res Rev 61(2): 89-104. (2009).
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41(10): 1088-93. (2009).
Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41(10): 1094-9. (2009).
Seshadri S, Fitzpatrick AL, Ikram MA, Destefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303(18): 1832-40. (2010).
Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67(7): 739-48. (2010).
Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA 305(13): 1322-6. (2011).
Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277(35): 32046-53. (2002).
Howlett DR, Bowler K, Soden PE, Riddell D, Davis JB, Richardson JC, et al. Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer’s disease. Histol Histopathol 23(1): 67-76. (2008).
Rohne P, Prochnow H, Koch-Brandt C. The CLU-files: disentanglement of a mystery. Biomol Concepts 7(1): 1-15 92016).
de Silva SH, Harmony JA, Stuart WD, Gil CM, Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry 29(22): 5380-9. (1990).
Mannini B, Cascella R, Zampagni M, van Waarde-Verhagen M, Meehan S, Roodveldt C, et al. Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers. Proc Natl Acad Sci USA 109(31): 12479-84. (2012).
Cascella R, Conti S, Tatini F, Evangelisti E, Scartabelli T, Casamenti F, et al. Extracellular chaperones prevent Abeta42-induced toxicity in rat brains. Biochim Biophys Acta 1832(8): 1217-26. (2013).
DeMattos RB. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 99(16): 10843-8. (2002).
Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 136(1): 22-31. (1995).
Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 21(10): 2312-22. (2007).
Prochnow H, Gollan R, Rohne P, Hassemer M, Koch-Brandt C, Baiersdörfer M. Non-secreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants and do not affect Bax-mediated apoptosis or the NF-kappaB signaling pathway. PLoS One 8(9): e75303 (2013).
Sansanwal P, Li L, Sarwal MM. Inhibition of intracellular clusterin attenuates cell death in nephropathic cystinosis [J]. J Am Soc Nephrol 26(3): 612-25. (2015).
Zhang F, Kumano M, Beraldi E, Fazli L, Du C, Moore S, et al. Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival. Nat Commun 5: 5775. (2014).
Yang CR, Yeh S, Leskov K, Odegaard E, Hsu HL, Chang C, et al. Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Res 27(10): 2165-74. (1999).
Killick R, Ribe EM, Al-Shawi R, Malik B, Hooper C, Fernandes C, et al. Clusterin regulates beta-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol Psychiatry 19(1): 88-98. (2014).
Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. Apolipoprotein J and Alzheimer’s amyloid beta solubility. Biochem J 316(Pt 2): 671-9. (1996).
Elder GA, Gama SM, De GR. Transgenic mouse models of Alzheimer’s disease. Mt Sinai J Med 77(1): 69-81. (2010).
IJsselstijn L, Dekker LJ, Koudstaal PJ, Hofman A, Sillevis Smitt PAE, Breteler N, et al. Serum clusterin levels are not increased in presymptomatic Alzheimer’s disease. J Proteome Res 10(4): 2006-10. (2011).
Xing YY, Yu JT, Cui WZ, Zhong XL, Wu ZC, Zhang Q, et al. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer’s disease. J Alzheimers Dis 29(3): 515-9. (2012).
Schurmann B, Wiese B, Bickel H, Weyerer S, Riedel-Heller SG, Pentzek M, et al. Association of the Alzheimer’s disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis 25(3): 421-4. (2011).
Won JC, Park CY, Oh SW, Lee ES, Youn BS, Kim MS. Plasma clusterin (ApoJ) levels are associated with adiposity and systemic inflammation. PLoS One 9(7): e103351 (2014).
Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, Gonos ES. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol 37(10-11): 1175-87. (2002).

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1207 - 1214]
Pages: 8
DOI: 10.2174/1567205014666170531080948
Price: $65

Article Metrics

PDF: 25